Aravax

Our next-generation immunotherapies use proprietary engineered peptides designed to precisely retrain the immune system to tolerate specific foods whilst avoiding treatment-induced acute allergic reactions, to produce safe and convenient treatments for food allergies. Aravax’s lead product for peanut allergy (PVX108) is currently being tested in Phase 2 trials in adolescents and children at clinics in Australia and the United States. Aravax was founded in May 2015 from intellectual property developed by Alfred Health and Monash University, and investment from the Medical Research Commercialisation Fund (MCRF), managed by Brandon Capital Partners. As part of closing a Series B funding round in January 2024, Aravax welcomed new investors Novartis Venture Fund, Tenmile, Breakthrough Victoria, Uniseed, and UniSuper to support the Phase 2 development of PVX108 and expand the product pipeline.